Brief: Abbisko Cayman Says FDA Grants Orphan Drug Designation To Abbisko's Absk061 For Achondroplasia
19/03/2026 01:20
March 19 (Reuters) - Abbisko Cayman Ltd 2256.HK: FDA GRANTS ORPHAN DRUG DESIGNATION TO ABBISKO'S ABSK061 FOR ACHONDROPLASIA Further company coverage: 2256.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration